In a recent trial, combined therapy targeting B-cells with rituximab (CD20 antibody) and belimumab (B-cell activating factor (BAFF) antibody) in SLE patients led to a significant decrease of anti-VZV IgG, whereas both anti-tetanus IgG and anti-rubella IgG remained stable [32]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.